Cognito Therapeutics Ltd. announced it raised $53.3 Million in an initial filing from an offering of $126 Million
Cognito Therapeutics Ltd. announced it raised $53.3 Million in an initial filing from an offering of $126 Million
07/01/22, 2:29 PM
Location
cambridge
Money raised
$53.3 million
Industry
health care
manufacturing
Company Info
Location
1218 massachusetts ave
cambridge, massachusetts, united states
Additional Info
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease.
Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.